Eli Lilly Valued at 39x with $65B Sales Eyes $2,000 Share Target
Eli Lilly shares have climbed 25% over the past year to $939, trading at 39x trailing earnings and 27x estimated 2026 EPS on 2025 revenue of over $65 billion. Orforglipron’s tiered pricing targets 100 million obesity patients and could generate $1.7 billion in 2026, supporting projections toward a $2,000 share price.
1. Stock Performance and Valuation
Eli Lilly shares have surged 25% over the past year to roughly $939, reflecting a valuation of 39x trailing adjusted earnings and 27x estimated 2026 EPS. This multiple reflects strong growth expectations against a backdrop of sector volatility noted over the last four years.
2. Revenue Expansion Trajectory
Revenue has grown from $28.5 billion in 2022 to $65.1 billion on a trailing twelve-month basis, with forecasts of $81.7 billion in 2026 and $94.9 billion in 2027. This expansion represents a near-45% increase over two years, driven by core diabetes and immunology franchises.
3. Orforglipron Launch and Pricing
The oral GLP-1 Orforglipron is priced at $25 per month for commercially insured patients, $50 for Medicare Part D and up to $349 for self-pay, unlocking demand among needle-averse and price-sensitive cohorts. Analysts project $1.7 billion in revenue in 2026, with potential peak sales of $35 billion.
4. Path to $2,000 Share Price
A model combining accelerated revenue growth, margin expansion and sustained valuation multiples underpins a scenario where shares could reach $2,000. Key drivers include continued market penetration of obesity treatments and successful geographic localization of manufacturing.